boston scientif corp engag develop
manufactur market medic devic
use broad rang intervent medic
specialti compani product technolog
use diagnos treat wide rang medic
vascular urolog women health chronic pain
condit compani headquart natick
reason report
estim chang analysi sales/earn
still one reiter rate price
reiter invest rate price target
share follow compani better consensu
expect importantli organ growth appear sustain
high- singl digit btg-relat growth appear stronger
oper headwind less burdensom street assum
new product pipelin remain replet opportun
result forecast realiz yoy increas
report revenu growth non-gaap earn growth
doubl accordingli share trade modestli
slower grow peer averag despit potenti rel
out-performance alreadi favor revenu earn growth
estim continu recommend share rate
reiter price reiter per share price
target assum ev/ebitda multipl
non-gaap earn multipl
chang estim increas former
revenu non-gaap earn estim billion
billion per share respect figur
likewis increas revenu non-gaap earn
estim billion per dilut share
per dilut share earn estim revis
summar tabl left
guidanc prior rang also
increas lower bound non-gaap cash earn guidanc
revis rang per share
non-gaap cash earn guidanc rang
per share versu pre-cal consensu estim
valuat summari share current valu
revenu ebitda cash
earn versu slower grow industri peer trade averag like
multipl respect figur
import disclosur analyst certif page report access current disclosur stephen
inc cover compani client may refer
summari oper review report sale billion pre-cal consensu billion
oper basi report organ basi figur intervent cardiolog
revenu million increas report led structur heart franchis mid-teen growth
complex pci importantli expect achiev structur heart revenu high end previous
establish guidanc rang million million led watchman acur lotu edg sentinel
peripher intervent revenu million increas report driven domest launch
venou stent eluvia de japan region growth atherectomi result compani cardiolog busi
gener billion revenu pre-cal consensu billion endoscopi revenu million increas
report led compani launch new product last month strength infect
prevent spyglass ds biliari hemostasi urolog pelvic health revenu million increas
report driven strength bsx core stone franchis compani benefit strong lithovu lithotripsi
laser sale result compani medsurg segment report revenu million pre-cal consensu
million cardiac rhythm manag revenu million increas report driven low-single-
digit growth defibril compani benefit strong uptak reson platform heartlog
emblem s-icd growth dilut single-digit declin bradi pace electrophysiolog revenu
million increas report driven rhythmia hdx map navig platform adopt
compani lumipoint softwar neuromodul revenu million increas report led
strong momentum compani vercis db due uptak cartesia direct lead launch
full-bodi patient mri label august result compani rhythm neuro segment report revenu
million pre-cal consensu million lastli report revenu million compani
btg acquisit intervent medicin segment gener million specialti pharma report million
oper period
report adjust gross margin flat year year high end compani
guidanc bsx cardiovascular busi report adjust oper margin decreas
year year medsurg busi report adjust oper margin year year
compani rhythm neuro busi report adjust oper margin year
year result report adjust oper margin year year lastli report
adjust tax rate result compani report non-gaap cash earn per share
free oper period gener approxim million adjust free cash
flow versu million prior year period compani forecast adjust free cash flow approxim
billion versu prior guidanc billion due slightli higher anticip work capit
need stem need higher inventori level support new product launch sale growth
divers new product pipelin lend confid sustain peer growth remain on-track
launch exalt-d single-us dispos duodenoscop potenti repres billion market
opportun well polarx europ combin two new devic lend support
continu market rate endoscopi growth highlight follow compani investor day june
plan new product cadenc taper enter beyond current plan launch
multipl new product lend addit support compani abil either sustain enhanc prevail
rate growth profit notabl continu anticip launch watchman flx lacc devic
 lotu edg valv system japan acur europ furthermor bsx coronari therapi
portfolio stand benefit domest launch megatron extend compani synergi
platform lux-dx compani implant cardiac monitor benefit cardiac rhythm manag
segment addit futur growth support synergi de ranger sfa dcb new icm monitor
dx forc sens cathet expand db platform next-gen spyglass visual system next gen
lithovu ureteroscop slate launch addit number offer simpli put
new product pipelin remain replet potenti
top-lin beat driven consensu
perform rhythm neuro medsurg
btg
research develop
sale market administr
opex in-lin expect
oper incom expect due
better anticip revenu
incom prior tax
beat due higher sale quarter
dollar million except per share data
compani report stephen inc estim
dollar million except per share data
inc compani report stephen inc estim
compani document stephen inc estim
becton dickinson compani
note data reflect stephen estim other consensu ep reflect adjust cash ep
stephen inc estim
compani document
consolid statement incom
million except per share data
good sold
research develop
sale market administr
fiscal period
fiscal period
fiscal period
incom prior tax
weight averag share issu outstand
compani report stephen inc estim
compani mention page
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
